Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
About this study
Compare use of the Magnet System in side-to-side duodeno-ileostomy (Surgery) with semaglutide (Medication).
- Condition
- Obesity (Disorder), Obesity & Overweight, Type 2 Diabetes (T2DM)
- Tested
- Magnet System, Semaglutide
- Sponsor
- GT Metabolic Solutions, Inc.
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Study condition: Obesity (Disorder), Obesity & Overweight, Type 2 Diabetes (T2DM)
- Body Mass Index (BMI) between 30 - 40 kg/m2 and qualifies for obesity treatment at the discretion of the treating investigator (i.e., must be assessed to qualify for both surgery and medication treatment to justify randomization).
- Type 2 diabetes (T2D defined as HbA1c ≥ 6.5%).
- Participant agrees to refrain from additional metabolic and bariatric (MBS) or reconstructive surgery that would affect body weight for the duration of the study.
- Participant agrees to refrain from taking any additional semaglutide-containing or other GLP-1RA medication for the duration of the study, regardless of randomization assignment (i.e., Surgery or Medication).
- Participant has been informed of the nature of the study and is willing and able to comply with requirements, including randomization, and provides written informed consent to participate in the study.
Exclusion 6
- Meets any of the contraindications for either treatment arm (Surgery: Magnet System; or Medication: semaglutide), thereby prohibiting randomization
- Current or previous metabolic and bariatric surgery (MBS) treatment in the previous 12 months (e.g., sleeve gastrectomy, intragastric balloons, adjustable gastric banding).
- Taking or treated with semaglutide, semaglutide-containing medications, or any other GLP-1RA medication in the previous 12 months.
- Pregnant, lactating or planning pregnancy during the clinical study and follow-up period.
- Currently participating in an investigational drug, biologic, or medical device or other interventional clinical study.
- Presence of other anatomic or comorbid conditions, or medical, social or psychological conditions that, in the investigator's opinion, would contraindicate either treatment arm or could limit the participant's ability to participate in the clinical study or to comply with follow-up requirements.
Where
1 site, 1 recruiting
Westmount Surgical Center
Westmount, Quebec, Canada
Contact
-
Lisa Griffin Vincent, PhD, MA
+1 763-200-1416 clinical@gtmetabolic.com
-
Josh Schumacher
+1 763-200-1416 clinical@gtmetabolic.com
Potential match only. Final eligibility is determined by the study team.